FDA Guides On COVID-19 Obstacles To ANDA Studies
Protecting Participants In Bioequivalence Studies Should Be Top Priority
Executive Summary
Specific guidance for ANDA sponsors on bioequivalence studies during the COVID-19 pandemic has been published by the US FDA.